Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)

Renal involvement is frequently present in patients with rheumatoid arthritis (RA). Approximately 15–25% of patients with RA have renal insufficiency, defined as a glomerular filtration rate (GFR) < 60 mL/min. Although concomitant use of methotrexate (MTX) has been proven to be more effective than administration of biological agents alone, MTX elimination is delayed in patients with renal insufficiency, which can increase the risk of adverse events. Therefore we often use MTX at...
Table 1  Baseline characteristics and tocilizumab therapy for patients with RA who were registered in the ACTRA-RI study (n=405)

| With renal insufficiency* (n=102) | Without renal insufficiency (n=303) | p Value† |
|---------------------------------|----------------------------------|---------|
| **Baseline characteristics**    |                                  |         |
| Age, years, mean (95% CI)       | 70.9 (69.4 to 72.5)              | 58.6 (57.1 to 60.0) | <0.0001 |
| Male/female, number             | 12/90                            | 66/237  | 0.027  |
| RA duration, years, mean (95% CI)| 13.7 (11.4 to 15.9)              | 9.9 (8.9 to 11.0) | 0.001  |
| CDAM, mean (95% CI)             | 22.8 (20.6 to 24.9)              | 22.0 (20.6 to 23.4) | 0.59    |
| High and moderate CDAM, number (%) | 92 (90.2)                        | 255 (84.2) | 0.13    |
| **Previous biologics, number (%)** |                                  |         |
| Anti-TNFα agents                | 53 (52.0)                        | 174 (57.4) | 0.34    |
| Abatacept                        | 4 (3.9)                          | 11 (3.6)   | 1.00    |
| Serum creatine, μmol/L, mean (95% CI) | 99.9 (87.5 to 111.4)            | 57.5 (53.0 to 61.9) | <0.0001 |
| Male                            | 111.0 (84.9 to 136.1)            | 83.1 (79.6 to 87.5) | <0.0001 |
| Female                          | 98.1 (84.9 to 111.4)             | 50.4 (45.1 to 54.8) | <0.0001 |
| Corrected eGFR, mL/min, mean (95% CI) | 42.9 (41.5 to 46.3)          | 81.8 (80.0 to 83.7) | <0.0001 |
| Severe renal insufficiency*, number (%) | 14 (13.7)                      | –         | –       |
| End-stage renal disease*, number (%) | 2 (2.0)                          | –         | –       |
| Haemodialysis, number (%)       | 1 (1.0)                          | 0         | –       |
| Haemoglobin, g/dL, mean (95% CI) | 11.5 (11.2 to 11.8)              | 12.2 (12.0 to 12.4) | <0.0001 |
| Male                            | 12.2 (10.8 to 13.5)              | 13.3 (13.0 to 13.7) | 0.03    |
| Female                          | 11.4 (11.1 to 11.8)              | 11.9 (11.7 to 12.1) | 0.004   |
| Anaemia‡, number (%)            | 54 (52.9)                        | 109 (36.0)  | 0.0025  |
| Use of erythropoietin, number (%) | 3 (2.9)                          | 0         | –       |
| Amyloidosis, number (%)         | 1 (1.0)                          | 0         | –       |
| Hypertension, number (%)        | 64 (62.7)                        | 94 (31.0)  | <0.0001 |
| Diabetes, number (%)            | 20 (19.6)                        | 31 (10.2)  | 0.014   |
| Concomitant use of MTX, number (%) | 33 (32.4)                        | 188 (62.0) | <0.0001 |
| **Discontinuation within the first 24 weeks** | |         |
| Total, number (%)               | 9 (8.8)                          | 25 (8.3)   | 0.86    |
| Adverse events, number (%)      | 8/9 (88.9)                       | 16/25 (64) | 0.23    |
| Other reasons, number (%)       | 1/9 (11.1)                       | 9/25 (36)  | 0.23    |
| MTX user§, number (%)           | 5/33 (15.2)                      | 15/188 (8.0) | 0.19    |
| MTX non-user§, number (%)       | 4/69 (5.8)                       | 10/115 (8.7) | 0.57    |
| Severe renal insufficiency, number (%) | 3/14                           | –         | –       |
| End-stage renal disease, number | 0/2                              | –         | –       |
| Adverse events within the first 24 weeks, number (%) | 9 (8.8)                          | 16 (5.3)   | 0.20    |
| MTX user§, number (%)           | 4/33 (12.1)                      | 9/188 (4.8) | 0.11    |
| MTX non-user§, number (%)       | 5/69 (7.2)                       | 7/115 (6.1) | 0.76    |
| Severe renal insufficiency, number (%) | 3/14                           | –         | –       |
| End-stage renal disease, number | 0/2                              | –         | –       |
| Severe adverse events¶, number (%) | 5 (4.9)                          | 6 (2.0)    | 0.12    |
| MTX user§, number (%)           | 1/33 (3.0)                       | 4/188 (2.1) | 0.56    |
| MTX non-user§, number (%)       | 4/69 (5.8)                       | 2/115 (1.7) | 0.20    |
| Severe renal insufficiency, number (%) | 1/14                           | –         | –       |
| End-stage renal disease, number | 0/2                              | –         | –       |

*An eGFR was first calculated using the following equation: eGFR (mL/min/1.73 m²) = 194 × (serum creatine (mg/dL))⁻¹.094 × (age)⁻⁰.287 × 0.739 (if female) and was then corrected for each patient's BSA (corrected eGFR = eGFR × BSA/1.73). Renal insufficiency is defined as an eGFR corrected for each patient's BSA <60 mL/min. Severe renal insufficiency is defined as a corrected eGFR <30 mL/min and ≥15 mL/min. End-stage renal disease was defined as a corrected eGFR <15 mL/min.

†Statistical analyses were performed using the independent-measures t test, the χ² test, or Fisher's exact test for comparisons of measures between the groups with and without renal insufficiency. For all tests, p values <0.05 were considered to indicate statistical significance.

‡Anaemia was defined as haemoglobin <11.5 g/dL (female) or <13.5 g/dL (male).

§There were no significant differences in rates of discontinuation, adverse events or severe adverse events between MTX users and non-users (the χ² test or Fisher's exact test). p Values for comparisons between MTX users and non-users: (1) discontinuation rates, p=0.14 in the renal insufficiency group and p=0.83 in the group without renal insufficiency; (2) adverse events, p=0.47 in the renal insufficiency group and p=0.62 in the group without renal insufficiency; (3) severe adverse events, p=1.00 in the renal insufficiency group and p=1.00 in the group without renal insufficiency.

¶Severe adverse events in the renal insufficiency group were heart failure after pneumonia, acute coronary disease, pyogenic arthritis, diverticulitis and aggravation of asthma; and those in the group without renal insufficiency were intestinal perforation, lung abscess, pleurisy, pulmonary mucormycosis, pneumonia and acute gastric haemorrhage.

ACTRA-RI, Actemra for RA patients with renal insufficiency; anti-TNFα, antitumor necrosis factor-α; BSA, body surface area; CDAM, clinical disease activity index; eGFR, estimated glomerular filtration rate; MTX, methotrexate; RA, rheumatoid arthritis; TCZ, tocilizumab.
reduced dosage for these patients in daily practice, which may result in inadequate responses.

The ACTRA-RI (Actemra for RA patients with renal insufficiency) study was designed to evaluate the efficacy and safety of tocilizumab (TCZ) therapy in the real-life registry of patients with RA and renal insufficiency. For this study, we registered all patients with RA who had begun TCZ therapy in participating hospitals as of January 2014 (total 405 patients with RA: 102 with renal insufficiency and 303 without). An estimated GFR (eGFR) was first calculated using an equation that had been officially approved by the Japanese Society of Nephrology. The calculated value was corrected for each patient’s body surface area to arrive at an absolute eGFR value for patients with RA.

As shown in Table 1, approximately 60% of the registered patients switched from another biological therapy because of inadequate responses or adverse events. Patients with renal insufficiency were significantly older and had RA for a longer duration. Mean serum levels of haemoglobin were significantly lower in the renal insufficiency group. Hypertension and diabetes, which are traditional risk factors for chronic renal disease, were more frequently complicated in this patient group. Sixty-eight per cent of patients with renal insufficiency received TCZ therapy without MTX because of concerns of MTX-related adverse effects. Nine patients (8.8%) with renal insufficiency and 25 (8.3%) without this complication discontinued TCZ therapy within the first 24 weeks. In both patient groups, the most frequent reason for withdrawal was adverse events. Regardless of MTX use, there were no significant differences in rates of dropout, adverse events, or severe adverse events between the groups with and without renal insufficiency. In addition, these rates were not significantly different between MTX users and non-users, even in patients with renal insufficiency.

A total of 371 patients (91.6%) completed the 24-week TCZ therapy. We divided these patients into four groups according to the status of MTX use and renal insufficiency. As shown in Table 2, significant improvements in mean clinical disease activity index values were observed at week 24 in all groups. Although the differences observed between these groups at baseline remained at week 24, mean haemoglobin levels were significantly increased over time during TCZ therapy, even in patients with renal insufficiency. There were no significant differences in efficacy among the four groups. Efficacy parameters in the renal insufficiency group were comparable with those in the group without this complication, whether patients received MTX concomitantly or not.

In this multicentre study, the 24-week TCZ therapy had good efficacy parameters as well as stable safety and tolerability profiles in patients with RA and renal insufficiency, regardless of MTX use. A recent randomised, double-blind clinical trial (ACT-RAY) indicated that there is no clinically relevant superiority of TCZ plus MTX therapy over TCZ monotherapy in patients with MTX-resistant RA even if some end points after 1 year favoured the combination treatment.

Shunsuke Mori,1 Tamami Yoshitama,2 Toshihiko Hidaka,3 Naoyuki Hirakata,4 Yukitaka Uekii5

1Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kohshi, Kumamoto, Japan

Table 2 Effects of tocilizumab on CDAI and haemoglobin levels in patients with RA who completed the 24-week treatment course (n=371)

| Patients with renal insufficiency (n=92) | Patients without renal insufficiency (n=279) | p Values between patient groups* |
|----------------------------------------|---------------------------------------------|---------------------------------|
| TCZ (n=64) | TCZ+MTX (n=28) | TCZ (n=106) | TCZ+MTX (n=173) | |
| **CDAI, mean (95%CI)**                  | **CDAI, mean (95%CI)**                      | **CDAI, mean (95%CI)**          | **CDAI, mean (95%CI)**          | **CDAI, mean (95%CI)**          |
| Week 0                                  | 22.9 (19.9 to 25.9)                         | 23.5 (20.1 to 26.9)             | 23.2 (20.7 to 25.7)             | 21.5 (19.6 to 23.3)             | 0.60                            |
| Week 24†                                | 9.8 (7.9 to 11.6)                           | 9.9 (7.3 to 12.4)               | 8.4 (6.9 to 9.8)                | 9.3 (8.1 to 10.6)               | 0.62                            |
| Low CDAI or remission, number (%)       | 7 (10.9)                                    | 1 (3.6)                         | 16 (15.1)                       | 27 (15.6)                       | 0.32                            |
| Week 24                                 | 37 (57.8)                                   | 16 (57.1)                       | 73 (68.9)                       | 109 (63)                        | 0.44                            |
| CDAI reduction ≥6.5, number (%)         | 48 (75)                                     | 22 (78.6)                       | 78 (73.6)                       | 120 (69.4)                      | 0.66                            |
| **Δ CDAI, mean (95%CI)**                | 13.1 (10.4 to 15.8)                         | 13.6 (9.5 to 17.7)              | 14.9 (12.7 to 17.1)             | 12.1 (10.5 to 13.8)             | 0.25                            |
| Haemoglobin, g/dL, mean (95% CI)        | 11.5 (11.1 to 11.9)                         | 11.5 (10.9 to 12.0)             | 12.3 (12.2 to 12.6)             | 12.1 (11.9 to 12.4)             | 0.008 vs 0.045                   |
| Week 0                                  | 12.5 (12.1 to 12.9)                         | 12.0 (11.5 to 12.4)             | 12.9 (12.7 to 13.2)             | 12.9 (12.7 to 13.2)             | 0.011 vs 0.001% vs 0.007**       |
| Week 24†                                | 36 (56.3)                                   | 12 (42.9)                       | 36 (34)                         | 65 (37.6)                       | 0.004 vs 0.015                   |
| Anaemia, number (%)                     | 24 (37.5)                                   | 9 (32.1)                        | 21 (19.8)                       | 25 (14.5)                       | 0.011 vs 0.001% vs 0.02**        |
| Δ haemoglobin, mean (95% CI)            | 0.96 (0.67 to 1.26)                         | 0.48 (0.16 to 0.81)             | 0.89 (0.61 to 1.16)             | 0.81 (0.65 to 0.98)             | 0.33                            |

* Values for comparisons of measures between the patient groups were determined using ANOVA (analysis of variance) with a Tukey HSD (honesty significant difference) post hoc test or the χ² test. For all tests, p values <0.05 were considered to indicate statistical significance.

† Mean CDAI and haemoglobin levels were significantly improved at week 24 in all four groups, when compared with those at baseline (p<0.0001 with the matched-pair t test).

‡ Based on comparisons between TCZ+MTX in the renal insufficiency group and that in the group without renal insufficiency.

§ Based on comparisons between TCZ+MTX in the renal insufficiency group and TCZ in the group without renal insufficiency.

¶ Based on comparisons between TCZ+MTX in the renal insufficiency group and TCZ in the group without renal insufficiency.

* Based on comparisons between TCZ+MTX in the renal insufficiency group and that in the group without renal insufficiency.
Correspondence to Dr Shunsuke Mori, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, 2659 Suya, Kohshi, Kumamoto 861-1196, Japan; moris@saisyunsou1.hosp.go.jp

Contributors All authors contributed to the study conception and design, acquisition of data, analysis and interpretation of data, and drafting of the manuscript with regard to important intellectual content.

Funding This study was supported by research funds from the National Hospital Organization (NHO), Japan.

Competing interests SM has received lecture fees from Chugai Pharmaceutical Co and Eisai Co, and a research grant from Chugai Pharmaceutical Co. YU has received a lecture fee from Chugai Pharmaceutical Co.

Patient consent Obtained.

Ethics approval This study is registered with the University Hospital Medical Information Network-Clinical Trials Registry (UMIN000014934). In addition, the ethics committees of participating hospitals approved the protocol for this study.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. *Rheumatology (Oxford)* 2008;47:350–4.

2. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1897–904.

3. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. *Ann Rheum Dis* 2010;69:1044–8.

4. Ng B, Chu A. Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. *Clin Rheumatol* 2014;33:21–30.

5. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53:982–92.

6. Redal-Baigorri B, Rasmussen K, Heaf JG. Indexing glomerular filtration rate to body surface area: clinical consequences. *J Clin Lab Anal* 2014;28:83–90.

7. Dougados M, Kissel K, Sheenan T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis* 2013;72:43–50.

8. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Ann Rheum Dis* 2014;73:803–9.

9. Fassett RG. Current and emerging treatment options for the elderly patient with chronic kidney disease. *Clin Interv Aging* 2014;9:191–9.

10. Anders Hj, Vliehauer V. Renal co-morbidity in patients with rheumatic diseases. *Arthritis Res Ther* 2011;13:222.